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Prevalence and importance of polymorphism occurring in pharmaceutical compounds are
well recognized. It is of great importance to prepare and select the right form from the
beginning during drug discovery and development. This review introduces the basic con-
cepts of “What is polymorphism?”, addresses a fundamental question of “Why do poly-
morphs form?”, and provides practical guidelines of “How to prepare polymorphs?” “How
to evaluate the relative thermodynamic stability between polymorphs?”, and “How to
analyze polymorphs?”. Moreover, case studies of pharmaceutically important polymorphs
are provided.
ª 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
The importance of polymorphism in pharmaceutical,
pigment, electrical industry is mainly due to two reasons. The
first one is because the existence of polymorphism is inevi-
table. In other words, polymorphism unavoidably occurs
during discovery, development, and/or manufacturing pro-
cess. As Ostwarld stated in 1899, “Almost every substance can
exist in two or more solid phases provided the experimental condi-
tions are suitable.” The other reason is because onemaywant it
to happen. In other words, one can change the physico-
chemical properties of a given compound by using differentfax: þ82 44 860 1606.
g Pharmaceutical Univer
sevier
University. Production anpolymorphs. Jean-Paul Garnier, CEO of GlaxoSmithKline said
that “About 50 % of drug candidates that enter clinical trials fail due
to efficacy and safety concerns, and the remaining 40% fizzle due to
patent concerns and issues like solubility and drug interaction.” [1,2]
This statement emphasizes the importance of manipulating
the desired physicochemical properties during drug
development.
Improvements in physicochemical properties can be ach-
ieved by altering the physical forms of a given compound such
as polymorphs, solvates, amorphous, salts, cocrystals, and/or
hydrates, etc. [3] Singhal et al. well summarized the physico-
chemical properties shown by different polymorphs with ex-
amples [4]. The physicochemical properties that can besity
d hosting by Elsevier B.V. All rights reserved.
Table 1 e Properties that can be altered by choosing
different polymorphic forms [7e9,12].
Thermodynamic properties Kinetic properties
 Melting and sublimation
temperatures, and vapor
pressure
 Enthalpy, entropy, and
heat capacity
 Free energy, chemical
potential, and solubility
 Dissolution rate
 Rates of solid state reaction
 Physical/chemical Stability
 Rate of nucleation/crystal
growth
Packing properties Surface properties
 Molar volume and density
 Conductivity, electrical
and thermal
 Refractive index
 Particle morphology
 Hygroscopicity
 Color
 Surface free energy
 Interfacial tensions
 Habit
Mechanical properties
 Hardness
 Tensile strength
 Compactibility and
tableting
 Handling, filtration,
flow and blending
 Cleavage
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 1 6 3e1 7 5164altered by choosing different polymorphs are summarized in
Table 1. The most important properties during drug discovery
and development include solubility, dissolution, bioavail-
ability, and physical/chemical stability. The best known
polymorphs showing a significantly different bioavailability in
human study are chloramphenicol palmitate [5] and mefe-
namic acid [6]. As the amount of the metastable form B pre-
sent in suspension formulation increases, the peak plasma
concentration of chloramphenicol palmitate in human in-
creases linearly.
Over the past two decades, the importance of pharma-
ceutical polymorphism has been arising in scientific com-
munity and industry as well as regulatory agencies.
Numerous reviews, book chapters, and literatures related to
pharmaceutical polymorphism have been published
[1,4,7e13]. This review introduces basic concepts of “What is
polymorphism?”, address fundamental questions of “Why do
polymorphs form?”, and provide practical guidelines of “How
to prepare polymorph?”, “How to evaluate the relative stabil-
ity between polymorphs?”, and “How to analyze poly-
morphs?”. Moreover, case studies of pharmaceutically
important polymorphs are provided.2. What is polymorphism?
Polymorphism occurs when a chemical compound crystal-
lizes with different internal structures. ICH Q6A defines
polymorphism as “some new drug substances exist in different
crystalline forms which differ in their physical properties. Poly-
morphism may also include solvation or hydration products (also
known as pseudopolymorphs) and amorphous forms.” [14] In a
strict sense, polymorphs have to retain the same chemical
composition and therefore, solvates or hydrates are defined as
pseudopolymorphs. Polymorphs can be categorized into two
subtypes: (1) conformational polymorphism and (2) packing
polymorphism. Conformational polymorphs occur when
conformationally different molecules exist in the crystallinestate. Since pharmaceutical compounds generally contain
flexible moieties in their molecular structures, there are
numerous examples of conformational polymorphs. In pack-
ing polymorphism, the molecules share the same molecular
conformations, but are packed differently in three-
dimensional space. Form I and II of acetaminophen are the
example of the most well known packing polymorphs [15,16].
In many known cases, several polymorphs crystallize
concomitantly. Concomitant polymorphism is headache for
pharmaceutical industry which seeks for polymorphic purity
or blessing for thosewho seeks for several polymorphic forms.
There are numerous examples of showing concomitant
polymorphism. Extensive study of concomitant poly-
morphism was conducted by Bernstein et al. [17].
Another interesting and frustrating phenomenon related
to polymorphism is “disappearing polymorphism.” [18e20] It is
generally believed that “any authentic crystal form should be
capable of being re-prepared, although selection of the right condi-
tions may require some time and trouble.” [21] In contrast to the
previous statement, “disappearing polymorphism” refers to a
situation where the previously prepared form no longer ap-
pears after obtaining the more stable form. There are quite a
few examples showing disappearing polymorphism including
benzylidene-dl-piperitone, benzocaine picrate, mannose, etc.
[18] “God-only knows where” seeds may play a role in crys-
tallization of disappearing polymorph similar to Dr. Breed case
for seeding phenomena [22].3. Why do polymorphs form?
System tends to move toward thermodynamically equili-
brated state. In otherwords, the system eventually transforms
to the most stable state. However, the routes to the final state
depend on kinetics as well as other factors as shown below.
Several mechanisms were proposed why the metastable form
appears first.
3.1. Ostwald’s rule of stages
Ostwald in 1897 stated, “.beim Verlassen irgend eines Zus-
tandes und dem U¨bergang in einen stabileren nicht der unter
den vorhandenen Verha¨ltnissen stabilste aufgesucht wird,
sondern der na¨chtsliegende,” and “die Form, welche unter
moglichst geringem Verlust an freier Energie erreicht werden kann.”
[23]When the system leavesany state, the transitionoccurs to a
more stable one, not the most stable one but the nearest one
under a given condition (Fig. 1).According to the theory, onehas
to observe all metastable forms before one finally observes the
stable form.However, it isnot always true.Weoftenobserve the
direct crystallization of the stable form from a solution.
3.2. Kinetic nucleation theory
In this theory, the rate of nucleation of metastable form and
the stable form are compared. In classical nucleation theory,
the rate of nucleation is derived using Arrhenius equation [24].
Jmeta ¼ Ameta exp

 DGmeta
kT

Eq. 1
Fig. 1 e Hypothetical diagrams of energy states of
polymorphs explaining Ostwald’s rule of stages.
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
 DGstable
kT

Eq. 2
where k is the Boltzmann constant, A, the rate of attachment
frequency, and DG, the activation energy for nucleation. The
possible scenarios follow: (1) Ameta > Astable, (2) Ameta ¼ Astable,
(3) Ameta < Astable, (4) DGmeta > DGstable, (5) DGmeta ¼ DGstable, (6)
DGmeta < DGstable. DG term includes the degree of supersatu-
ration, temperature of crystallization, and interfacial tension.
The rate of nucleation is expressed as:
J ¼ A exp
"
 16pg
3y2
3k3T3ðln SÞ2
#
Eq. 3
where g is the interfacial tension, T, temperature, S, degree of
supersaturation, and y molecular volume.
On the basis of classical nucleation theory, the rate of
nucleation of two polymorphic forms depends on the fre-
quency factor, temperature, interfacial tension, and super-
saturation (Eq. (3)). One can assume that the melting point of
the stable form is higher than that of metastable form and
therefore, the degree of supersaturation is higher for the sta-
ble form at the same crystallization temperature [25]. In gen-
eral, the attachment frequency of the metastable form will be
higher than that of the stable form since entropy of the
metastable form is higher that of the stable form. The effects
of the attachment frequency and the supersaturation by
supercooling oppose to each other. It is likely that the rate of
nucleation for the stable form is higher at low temperatureA B
Fig. 2 e The rate of nucleation between two po(high degree of supersaturation) and the transition occurs
near the melting temperature (low degree of supersaturation)
since the contribution of degree of supersaturation will
diminish near the melting temperature.
According to Ostwald’s rule of stages, the rate of nucleation
of themetastable form is always higher than that of the stable
form over all temperature ranges. However, kinetic nucleation
theory suggested that the rate of nucleation of the metastable
form is never higher over the entire supersaturation ranges
(Fig. 2).
3.3. Cross nucleation
Cross nucleation occurs when a polymorph nucleates on
another polymorph. Cross nucleation have been observed for
small organic molecules as well as polymers from a solution
or from the melt [26e30]. During cross nucleation process,
several different polymorphs nucleate on each other. The
polymorphic formwith a fastest growth ratewill be eventually
observed regardless of the rate of nucleation. It is also noted
that a certain polymorph selectively nucleates on a specific
polymorph: in the case of 5-methyl-2-[(2-nitrophenyl)amino]-
3-thiophenecarbonitrile (ROY) compound, form YN specif-
ically nucleates on R while, R and R05 nucleate on Y04 [27].
Cross nucleation does not occur following the thermodynamic
stability, a less or a more stable polymorph can nucleate on
the surface of the existing polymorph. In a certain case, new
forms of ROY, R and R05, were discovered via cross nucleation.
They had never been spontaneously nucleated before.
Themechanistic study of cross nucleation showed that the
initial polymorphs formed, the growth rate, the nucleation
rate, thermodynamic stability, defects, lattice matching,
crystallographic orientation, and formation of interfacial
transition layers all play major roles in inducing cross nucle-
ation [31,32].
In the case of D-mannitol, a form seed always induces the
crystallization of the a form, but the b polymorph seed yields
the b or a formwhereas, the g form seed yields the a form [28].
As we mentioned previously, the final polymorph is the one
with the fastest growth rate irrespective of the initial nuclei
formed during crystallization. From this, one can assume that
the a form grows the fastest among the three polymorphs.
However, the b polymorph can nucleate on the a form when
the solution is quench-cooled. Since growth rate can change
as a function of the degree of supersaturation, temperature, or
interfacial tension, the final polymorphic form originatingC
lymorphs as a function of supersaturation.
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tallization conditions. Polymorph selectivity of highly poly-
morphic ROY compounds via cross nucleation was further
conducted by Yu et al. Yu et al. explained that growth rate, the
rate of heterogeneous nucleation of the new polymorph, and
defects play major roles in determining the final polymorph
obtained via cross nucleation [27]. However, they concluded
that the relative stability or lattice matching is insufficient to
explain polymorph selectivity by cross nucleation.
The selectivity of polymorphic form resulting from cross
nucleation was also investigated using molecular dynamics
[33,34]. Molecular dynamics (MD) study showed that cross
nucleation occurs only when the free energy of two poly-
morphs are almost equivalent and confirmed that the poly-
morph with the fastest growth rate will appear in the end. MD
study also showed that common lattice planes between two
cross nucleated polymorphs at the interface are necessary. An
interfacial transition layer is required to induce cross nucle-
ation between polymorphs that do not share structural
matching at the interface [33].3.4. Heterogeneous two-dimensional nucleation:
chemotaxy, ledge-directed epitaxial growth, and two-
dimensional lattice matching
According to the classical nucleation theory, homogeneous
two-dimensional nucleation requires less energy for mole-
cules to nucleate than three-dimensional nucleation.
On the basis of the classical nucleation theory, the energy
required for homogeneous three-dimensional/two-
dimensional nucleation follows (Eq. (4)):
DG ¼ agþ yDGy Eq. 4
where a and y are the area and volume of the nucleus.
When we consider the attachment of adsorption layer on
the surface of the crystal as homogeneous two-dimensional
nucleation/growth, the energy required for two- dimensional
nucleation follows (Eq. (5)):
DG2D ¼ 2prhgþ pr2hDGy Eq. 5
where the circular disc of radius is r, height, h, interfacial
tension, g.
DG3D ¼ 4pr2gþ 43pr
3DGy Eq. 6
When compared to the energy requirement for three-
dimensional nucleation (Eq. (6)), one can intuitively know
that two-dimensional nucleation is energetically favorable
than three-dimensional nucleation and therefore, lower de-
gree of supersaturation is enough for two-dimensional
nucleation to occur as compared to three-dimensional
nucleation. However, it is noted that the heterogeneous two-
dimensional nucleation can be different from homogeneous
two-dimensional nucleation in a sense that the interfacial
tension between two layers from different crystals contrib-
utes to the energy required for the attachment of adsorption
layer.
When heterogeneous two-dimensional nucleation is
considered, the interfacial tension is an important factorcontrolling the nucleation process. The factors controlling the
interfacial tension between two layers include chemical
interaction [35], formation of monolayer between deposit and
substrate [36], and/or geometric configurations including
molecular conformations at the interface between layers,
ledge-directed epitaxy [37,38], or two-dimensional lattice
matching [39e42].
Ledge-directed epitaxy is a specific form of two-
dimensional heterogeneous nucleation where a material nu-
cleates and grows on a substrate with a specific geometric
match. Interplanar dihedral angles between two close planes
of ledge site and two close planes of prenuclear aggregates are
crucial factors leading to the ledge-directed epitaxial growth.
Organic molecules nucleated on organic single crystal sub-
strates with small free energy via ledge-directed epitaxy [37].
The contributions from chemical interaction between deposit
and substrate is small while, topographic structure, lattice
parameters at ledge sites, symmetry constraints, and molec-
ular composition play a major role in determining the nucle-
ation of organic crystals on substrates.
Another geometric configurations leading to two-
dimensional nucleation is two-dimensional lattice matching
between overlay plane and the substrate [39]. Two-
dimensional lattice matching can be evaluated using the
epitaxy score. The epitaxy score is calculated using Geomet-
rical GRACE (global real-space analysis of crystal epitaxy) that
is available and free for academic purpose [43]. Discovery and
stabilization of YN polymorph of ROY compound was
explained by using two-dimensional lattice matching [39].
3.5. Additive-induced polymorph selection
Molecular recognition at the interface has been well recog-
nized in fields of nucleation/growth [44,45], supramolecular
chemistry [46], and resolution of enantiomer [47e53]. Tailor-
made additives or structurally related impurities inhibit or
enhance nucleation/growth process of parent crystals [54e56].
Carefully designed additives can inhibit the nucleation by
being incorporated into the prenuclear aggregates/crystals or
by binding to nuclei/crystals. There are three scenarios
possible for inhibition of nucleation/crystal growth by addi-
tives. First, additives prevent prenuclear aggregates of a
particular form from growing into a nucleus with a critical
radius by creating defects in the aggregates. As a result, pre-
nuclei redissolve back into the solution. In this respect, addi-
tives can decrease the rate of nucleation by increasing the
critical supersaturation for nucleation and/or interfacial ten-
sion. Second scenario is that additives can favorably attach to
prenuclei of a certain form of polymorph or enantiomers.
However, other polymorph remains unaffected by additives.
As a result, the unaffected prenuclei grow into the nuclei with
a critical radius size, and become resulted crystals. The third
scenario is that additives attach to the fastest growing face of
the stable polymorph. The inhibition of growth of the fastest
growing face prevents the stable form from growing. As a
result, the metastable polymorph crystallizes.
The same analogy applies to inhibition of crystal growth by
additives. Certain additives such as structurally related addi-
tives, can easily attach to a certain face of crystals as host
molecules do. However, additives will inhibit the attachment
Table 2 e Methods of obtaining polymorphs.
Method of obtaining polymorphs
1 Crystallization from a single or mixed solvents/HTS [62e66]
2 Thermal activation of the solid substrates [67]
3 Crystallization from the melt [73e75]
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to steric hindrance. Growth inhibition of a certain form results
in growth of unaffected form such as different polymorph
[57,58]. Inhibition of growth of a specific faces will result in
changes in morphology, dissolution rate, and/or polymorph
selection [54].
4 Desolvation/dehydration of solvates/hydrates by heat
or by reslurry [85,91]
5 Crystallization in nano-confined structures [96,98,100]
6 Seeding/pseudoseeding [101,102]
7 Solution mediated polymorphic transformation/slurry
conversion method [103e106]
8 Solid-state polymorphic transformation [85,107]
9 Mechanical activation of the solid substance [11,108],
10 Crystallization in a capillary tube [109,110]
11 Exposure to vapor at high or low humidity [111e113]
12 Exposure to organic vapor [90]
13 Directed crystallization on molecular substrates [37e42]
14 Crystallization in the presence of tailor-made
additives [44e58]
15 Laser induced crystallization [114,115]
16 Crystallization from a supercritical fluid [116e118]
17 Structure prediction [119e123]4. How to prepare polymorphs?
Considering the importance of polymorphism in pharma-
ceutical industry, polymorph screening is an essential part of
drug discovery and development process. As McCrone stated
in 1965, “It is at least this author’s opinion that every compound has
different polymorphic forms, and that, in general, the number of
forms known for that compound is proportional to the time and
money spent in research on that compound.” [59] After a decade,
Kuhnert-Brandstatter stated that “probably every substance is
potentially polymorphous. The only question is, whether it is possible
to adjust the external conditions in such a way that polymorphism
can be realized or not.” [60] On the basis of the above statements,
it is clear that polymorphs can be obtained when external
conditions are adjusted. How extensive should polymorph
screening be conducted during early development process is
controversial and depends on decision of the company. While
the facts that the attrition rate of drug candidates during early
development process is very high, conducting an exhaustive
polymorph screening is time and money consuming. How-
ever, the appropriate polymorph selection during drug
development process to address desired stability and physi-
cochemical property issues should not be shadowed. The
methods to prepare polymorphs are summarized in Table 2.
Some important and/or newly developed methods are dis-
cussed in detail.
4.1. Crystallization from a single or mixed solvent
Generally, polymorph screening is conducted by crystallizing
substances from a single or mixed solvent via cooling crys-
tallization, evaporation, or antisolvent crystallization. Selec-
tion of appropriate solvents is challenging. Gu et al. have well
summarized the physicochemical properties of 96 solvents
which are often used for polymorph screening [61]. The sol-
vents were classified into 15 categories using cluster statistical
analysis where solvent parameters such as hydrogen-bond
acceptor/donor propensity, polarity/dipolarity, dipole
moment, dielectric constant, etc. are variables. One can select
a solvent from each category for initial polymorph screening
and mix solvents from different categories.
In addition, heating and cooling rates, crystallization
temperature, evaporation rate, the degree of supersaturation,
the rate of agitation, pH of the media are variables which can
affect crystallization process and thus, polymorphs formed.
Considering the number of organic solvents and the combi-
nations of solvents as well as factors affecting crystallization,
thousands of crystallization experiments need to be con-
ducted with small amounts of drug candidate during poly-
morph screening. Attempts to obtain polymorphs using
solution crystallization can be made by high-throughput
screening technology [62e66].4.2. Thermal activation of the solid substrates
Before we discuss thermal activation method to obtain a
desired polymorph, we need to know the thermodynamic
relationships between polymorphs. Any given two poly-
morphs can be either monotropic or enantiotropic. Mono-
tropic relationship occurs when one of polymorphs is stable
over entire temperature range (Fig. 3a). In the case of enan-
tiotropic system, the transition temperature at which the free
energy between two polymorphs is equal occurs below
melting point (Fig. 3b). In other words, one form is stable
below the transition temperature, and the other form is stable
above the transition temperature.
In an enantiotropic system, the metastable form at room
temperature can be obtained by heating the stable form above
the transition temperature. In amonotropic system, the stable
form at room temperature can be obtained by heating the
metastable form at any temperature. The rate of trans-
formation can be facilitated by heating themetastable form at
high temperature. If one starts with the stable form, it is
impossible to obtain the metastable form by thermal activa-
tionmethod in amonotropic system. For example, flufenamic
acid I which is metastable form at room temperature can be
obtained easily by heating flufenamic acid III above 105 C [67].
The transition temperature can be estimated by observing the
transition events during DSC measurements [68], by calcu-
lating the Gibbs free energy difference between polymorphs
over temperature ranges via direct heat capacity measure-
ment [69], by constructing the van Hoff’s plot via solubility
measurements of polymorphs over temperature ranges
available [6,70], or by slurrying the mixtures of polymorphs
over temperatures available, etc [71,72].4.3. Crystallization from the melt
Crystallization from the melt is similar to crystallization from
amorphous material. Since amorphous is a
Fig. 3 e Energy/temperature diagrams of dimorphic systems (a) monotropic systems, (b) enantiotropic systems (Tp:
transition point; Tf: fusion point; H: molar enthalpy; G: molar free energy; S: molar entropy; A, B: crystalline modifications; l;
liquid phase).
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 1 6 3e1 7 5168thermodynamically unstable form as compared to corre-
sponding crystalline materials, amorphous materials tend to
crystallize. There are numerous papers describing crystalli-
zation/devitrification behavior from amorphous materials.
Generally, crystallization from amorphous material is prob-
lematic since crystallization from amorphous alters physico-
chemical properties of a drug compound. However, one can
use crystallization from amorphous as a technique to grow
desired polymorphic forms. Depending on the external stress
applied to amorphous, crystallization from themelt generates
different polymorphic forms with different kinetics and
mechanism [73e75]. It is reported that crystallization from the
melt is the only method to generate metastable forms, II (or b)
and III (or g) of nifedipine, [76,77] as well as the metastable
form III of acetaminophen [78].
4.4. Desolvation/dehydration of solvates/hydrates by
heat or by reslurry
As the number of experiments during screening process in-
creases with an advance in high-throughput screening and
polymorphic screening methods, the number of solvates/hy-
drates discovered during screening process also increases
[62,63,79e85]. When desolvation or dehydration occurs, sol-
vates/hydrates can undergo a phase transition and thus, form
non-solvated/anhydrous polymorph [86,87] or can lose crys-
tallinity and thus, form amorphous [88]. In other cases,
isomorphic desolvates/dehydrates form, meaning that sol-
vent/water molecules leave crystals without affecting the
crystal structures of solvates/hydrates [89,90]. Generally,
desolvation/dehydration process is conducted at low relative
humidity or low organic vapor pressure. Recently, it has been
shown that desolvation using reslurrying solvates in a solvent
with poor solubility at low or high temperature yields phar-
maceutically relevant polymorphs [91].
4.5. Crystallization in nano-confined structures
We do not define nano-materials just bymeasuring the size of
materials, although the definition of nano-materials is still
controversial. However, it is at least clear that nano-materialsshow size-dependent properties such as optical [92], elec-
tronic [93], or magnetic properties [94] which are different
from macro-sized crystals. Nano-materials show an
extremely high surface-to-volume ratio compared to macro-
sized materials. As a result, the surface effects become
increasingly important as the size of materials decreases
[95e97].
A clear example of abnormal property of nano-materials is
the melting point depression as a function of size [98,99]. The
relationship can be written according to the Gibbs-Thomson
equation:
TmðdÞ ¼ Tbulkm 
4Tbulkm s
dDHbulkm r
Eq. 7
where DHbulkm is the equilibrium heat of melting and T
bulk
m the
equilibriummelting temperature of bulk crystals, r density of
bulk crystal, d the pore diameter of cylindrical nano-confined
structures. s, the effective surface energy of nano-sized
crystals confined in the cylindrical pores can be obtained by
plotting the melting point depression as a function of diam-
eter of nano-sized crystals. The diameter of nano-sized crys-
tals is assumed to be the same as pore size of nano-confined
structure. On the basis of the Eq. (7), it is clear that the size of
crystals affects the total free energy of the nano-sized crystal.
The Gibbs free energy equation can be rewritten including the
contribution of the effective surface energy of nano-sized
crystals:
DGnanoCA ¼ DGbulkCA 

A
V

snanoc
rbulkc

Eq. 8
where DGnanoCA is the Gibbs free energy difference between liq-
uids and nano-sized crystals, DGbulkCA the Gibbs free energy
difference between liquids and bulk crystals, A the surface
area, V the volume, snanoc the effective surface energies of
nano-sized crystals, rbulkc the density of bulk crystals.
The relative stability of polymorphs also changes as a
function of crystal size (pore size) as well as temperature. By
combining Eq. (7) and Eq. (8), the relative stability between two
nano-sized polymorphs can be obtained and plotted as a
function of temperature. Crystals can be grown in nano-sized
pores to reverse the relative thermodynamic stability between
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 1 6 3e1 7 5 169polymorphs [96,97], and to improve the physical stability of
the metastable polymorph in case of acetaminophen form III
[98], to obtain unknown polymorphs such as d-pimelic acid, b-
suberic acid, and b-coumarin or to crystallize the stable forms
such as mefenamic acid, glycine, and ROY that are not easily
obtainable under normal crystallization conditions [97e100].4.6. Seeding
Seeding facilitates the crystallization process via heteroge-
neous or secondary nucleation. Seed crystals can be exactly
the same form of interest, a pseudo-seeds that are structurally
compatible to the desired form of interest but not exactly the
same, or the one that is not related to the form of interest [24].
Seeding with a desired polymorphic form is a commonly used
technique for controlling polymorphic form during industrial
crystallization [101]. Pseudoseeding is often used when the
seed of interest is not available [102]. It is usually expected
that the polymorphic form of seeds will crystallize out. How-
ever, it should not be forgotten that the seeding can also
facilitate the crystallization of some undesired form(s)/
another polymorphic form(s) when those seeds serve as
templates for cross nucleation or epitaxial growth. In those
cases, the form that grows faster than the seed crystals will
eventually crystallize out.4.7. Solution mediated polymorphic transformation/
slurry conversion method
Solution mediate polymorphic transformation (SMPT) is a
fast, easy, and reliablemethod to obtain the stable polymorph.
If one is fortunate, one may obtain the series of polymorphs
following the Ostwald’s rule of stage. SMPT occurs via the
dissolution of the metastable form followed by nucleation/
growth of another form which is more stable than the previ-
ous form. The thermodynamic driving force for SMPT is the
solubility difference between polymorphs. The kinetic factors
governs the rate of solution-mediated polymorphic trans-
formation including solubility difference between poly-
morphs in a given solvent, the dissolution rate of theTable 3 e Thermodynamic rules to determine the relative therm
dimorphic system. [127,128].
Heat of transition rule Polymorphs are enantiotropically rela
melting form is observed
Polymorphs are monotropically relate
observed
Heat of fusion rule Polymorphic pairs are enantiotropical
otherwise they are monotropically rel
Entropy of fusion rule Polymorphs are enantiotrope if the hi
are monotrope
Heat capacity rule Polymorphic pairs are enantiotropical
low melting form at a given temperatu
Density rule One polymorph with a higher density
with a lower density
Infrared rule One polymorph with a higher absorpt
crystal may be assumed to have large
Solubility rule If the higher melting form has higher
enantiotropically related. In a monotrmetastable form, and the rate of nucleation/growth of the
stable form [71,103]. In addition, if dissolution rate limited
SMPT occurs, particle size will play an important role in
determining the rate of SMPT.
SMPT is also an easy and simple method for obtaining
solvates/hydrates of a given compound. Generally, solvate/
hydrate is the most stable form in a given solvent if a com-
pound shows solvate forming tendency. When specific sol-
vates/hydrates are needed, solvent-free crystals can be
slurried in the given solvent for an extend period of time.
When two solvent-free polymorphs are considered, the ther-
modynamic stability of two polymorphs is determined by the
Gibbs free energy difference at a given temperature and
pressure. When hydrate/anhydrous forms are considered, the
water activity in the solvent contributes to the relative phys-
ical stability and thus, the resulting form [104,105]. It was
found that the water activity in a solvent mixture plays a
major role in determining the resulting crystalline forms of
theophylline regardless of the corresponding organic solvent
[106].5. How to evaluate the relative
thermodynamic stability between polymorphs?
The relative thermodynamic stability between polymorphs
are of great interest due to the physical stability and solubility
issues and play a decisive role in determining the polymorphic
form to be used in formulation. Table 3 summarize the most
re-known “the thermodynamic rules” to determine the relative
thermodynamic stability and the thermodynamic relations of
a dimorphic system by Burger and Ramberger [124,125].
The thermodynamic relationships can be experimentally
determined by calculating the Gibbs free energy difference
between polymorphs over temperature ranges via direct heat
capacitymeasurement, by constructing the van Hoff’s plot via
solubility measurements of polymorphs over temperature
ranges available, or by slurrying the mixtures of polymorphs
over temperatures available, etc. similar to those which were
described in “How to Prepare Polymorphs?” section (Fig. 4).odynamic stability and the thermodynamic relations of a
ted if endothermic heat of transition from low melting form to high
d or the transition temperature is higher if exothermic transition is
ly related if the low melting form has the higher heat of fusion,
ated
gh melting form has the lower entropy of fusion, otherwise they
ly related if the high melting form has higher heat capacity than the
re
can be assumed to be more stable at 0 K than the other polymorph
ion band in the infrared spectrum of a hydrogen-bond molecular
r entropy than the other with a lower absorption band
solubility above the transition temperature, polymorphs are
opic system the higher melting form always has a lower solubility
Fig. 4 e Schematic energy-temperature phase diagram of
donepezil polymorphs I, II, C, and F. Adapted from Ref. 69.
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Most of the solid state characterization techniques except
single crystal X-ray analysis are complimentary. Table 4 shows
somecharacteristic featuresofdifferent techniques in termsof
destructiveness, sample amounts, analysis time, etc. Powder
X-ray diffraction (PXRD) is the front-line technology to analyze
polymorphs. PXRDpatternsbetweenpolymorphsarenormally
very distinct as compared to FTIR/Raman spectra. It can beTable 4 e Some practical information regarding the solid state
Techniques Analysis
time
Sample (mg) Destructiveness
PXRD [112,126,127] 3e8 min 10e30 X
DSC [128e130] 20e30 min 2e4 O
TGA 20e30 min w10 O
Single crystal
X-ray
1e2 day Single
crystal
O
FTIR (Pellet) 10e20 min 3w (pellet) O
FTIR (ATR) 10e20 min 10w X
FTIR (Probe) 3 s 10w X
FT-Raman [131,132] w20 min 10w O
FT-Raman
(Probe) [133]
3 s 3w X
HSM [134] 20e30 min 2e3 X
ssNMR [135e137] 1 h 20e30 O
DSC e differential scanning calorimetry; TGA e Thermogravimetry analy
O ¼ Yes X ¼ No.used for quantitative analysis of polymorphmixtures, and for
an analytical tool for high-throughput screening with some
modifications. However, when the reference powder patterns
of pure forms are not available, it is often difficult to realize if
thepowderpattern is fromthemixtureorpurematerial. This is
where single crystal X-ray analysis technique is necessary.
Single crystal X-ray analysis is a definitive tool to obtain the
crystal structural information of polymorphs and can be used
for obtaining the calculated powder patterns. However, it is
often very difficult to obtain a single crystal suitable for single
crystal X-ray analysis, especially metastable forms. Crystal
structure information can also be deduced from the powder
patterns. However, it is difficult to obtain a good quality data
suitable for structure elucidation using laboratory powder X-
ray diffractometer equippedwithCuKa radiation. Therefore, it
is often necessary to obtain the data from synchrotron X-ray
radiation source.7. Examples of polymorphism of
pharmaceutically important compounds
7.1. Aspirin
Aspirinwas synthesized by Felix Hoffmann in 1897 for the first
time, and has been on the market since 1899. Since then,
aspirin has been one of the most widely used drugs in the
world, and it is apparent that ithasbeencrystallized repeatedly
for a long time.With sucha longhistory, aspirinwas thought to
be one of the compounds that did not show polymorphism.
Then, came the debate regarding the existence of new poly-
morphic forms of aspirin [138]. But the crystal structure infor-
mation of a new polymorphic form (form II) obtained from
single crystal structure analysis was not revealed until 2005
[139]. Even after the crystal structure of aspirin form II was
discovered, the existence of polymorphic form is stillcharacterization method of polymorphs.
Preparation Quantitation
Simple O Difficult to differentiate the
mixtures, first-line to analyze
polymorphs, HTS
Simple O Easy to detect the mixtures
Thermodynamic relationships
Simple X Existence of solvates/hydrates
Idea of how strong solvents
interact with molecules
Difficult X Definitive tool
Difficult O Molecular interactions
Simple O No sample preparation
Simple O On-line monitoring
Simple O Molecular interactions, HTS
Simple O On-line monitoring
Simple X Visual observation
Difficult O Racemate, Chirality
sis; HSM e Hot-stage microscopy; HTS e High-throughput screening;
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between two polymorphic domains [140,141]. However, it is
clear that the two polymorphic forms show significantly
different solid state properties such as dissolution rate, me-
chanical properties, crystal habit, melting point, and pKa.
7.2. Acetaminophen
Acetaminophen is a widely used analgesic and antipyretic
drug. Acetaminophen shows three polymorphic forms, I, II,
and III [15,16,142e144]. Form I and II are known to show
packing polymorphism where molecular conformations are
the same, but the crystal packings are different. Commercial
form of acetaminophen polymorph is form I. Acetaminophen
form II is slightly more soluble than form I and suitable for
direct compression, but is less stable and susceptible to
transforming to form I during compression and storage [145].
Form II can be obtained by crystallizing solids in benzyl
alcohol at high temperature, by cooling the melt, by adding
carboxylic acid additives, or by using evaporation method.
Form III is known to be highly unstable, and obtained by
cooling the melt. It undergoes solid state polymorphic trans-
formation to form II within hours [146]. Recently, it was shown
that form III can easily crystallize in nano-confined structures
with a pore size ranging from 10 to 103 nm [98].
7.3. Atorvastatin
Atorvastatin calcium is an inhibitor of 3-hydroxy-3-methyl-
glutaryl-coenzyme A (HMG-CoA) reductase, and is used for
lowering blood cholesterol. Atorvastatin was developed and
marketed by Pfizer under the trade name Lipitor. It was the
number one selling drug inUSuntil its patent expiredat 2011.At
least 60 polymorphic forms/solvates/hydrates have been
patented and/or published [147]. Surprisingly, none of single
crystal structure information has been reported on CSD (Cam-
bridge Structural Database, 2013). It will be very interesting to
knowwhat makes atorvastatin calcium highly polymorphic.
7.4. Ritonavir
Ritonavir is an antiretroviral drug belonging to protease in-
hibitor class and is used to treat HIV-1 infection. Ritonavir was
marketed in 1996, but had to bewithdrawn from themarket in
1998 due to a sudden appearance of the stable and less soluble
form II in Norvir semi-solid capsules [163]. The metastable
form is more than five times soluble than the stable form II in
a mixture of water and ethanol. It was reported that degraded
impurity provided seeds for heterogeneous nucleation of the
stable form. Later, three more forms including two solvates
and one unsolvated formwere discovered by high-throughput
screening [64]. Almost 2000 experiments were conducted with
2 g of the API. Form II is reported to be the stable form among
the five polymorphic forms isolated so far.
7.5. Highly polymorphic form, axitinib
Axitinib is a tyrosine kinase inhibitor that targets the vascular
endothelial growth factor and is known to interrupt tumor
angiogenesis and thus, prevent the growth of cancer cells. 60solvates, polymorphs of solvates, and five anhydrous forms
were discovered [91]. Conventional crystallization methods
did not lead to the discovery of the most stable polymorph.
The stable anhydrous form was obtained via reslurrying the
solvates at high temperature, and used in commercial
formulation under trade name Inylta [164]. Understanding of
the desolvation pathway was critical for obtaining the most
stable polymorph of axitinib.
8. Summary
Polymorph screening, selections, and controls play parts in
determining the success of new drug discovery and develop-
ment. With the advancements in understanding of solid state
chemistry along with new analytical techniques, realization
of crystal engineering and molecular level design of pharma-
ceutical solids with desired physicochemical properties are
now closer. It has been recognized that molecular level un-
derstanding of nucleation of polymorphs is necessary to
control crystallization of polymorphs and comprehend the
issues relevant to physical stability. Thermodynamics, ki-
netics, and supramolecular chemistry via molecular recogni-
tion are crucial factors in understanding the nucleation of
polymorphs. Appropriate manipulation of factors affecting
the nucleation of polymorphs is the key for the formation of
new polymorphic forms which might have the desired phys-
icochemical properties.
We have described some important factors affecting
nucleation processes of polymorphs in terms of kinetics, ther-
modynamics, and molecular recognition and summarized
some pharmaceutically important and/or newly developed
methods of preparing polymorphs. Some of the pharmaceuti-
cally important polymorphs were also introduced. Although a
certain polymorphic form is still obtained serendipitously
[139e165], it is hoped that this review will promote the under-
standing of polymorphism inmolecular level andmake ease of
undertaking polymorph screening and selections.
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